

cPLA₂, wherein said inhibitor interacts with one or more atoms of said one or more amino acids in the cPLA₂ active site, and wherein said one or more atoms is selected from the group consisting of:

CB and O_γ atoms of Ser228;
O_{δ1} and O_{δ2} atoms of Asp549 and Asp575;
CB, CG, CD, NE, CZ, NH1 and NH2 atoms of Arg200, Arg413 and Arg579;
Backbone carbonyl oxygen of Trp393;
N_{δ2} and O_{δ1} atoms of Asn555;
Atoms CD1, CE1, CG, CZ, CE2, and CD2 of Phe397, Phe681, Phe683 and Phe199;
CG, CD1, NE1, CE2, CZ2, CH2, CZ3, CE3 and CD2 of Trp232 and Trp393;
CB and O_γ atoms of Ser577;
Atom s CB and S_γ of Cys331;
Atoms OE1 and OE2 of Glu589;
Atoms CB, CG, CD, CE and NZ of Lys588;
O_{γ1} atom of Thr680;
OE1 and OE2 atoms of Glu418 and Glu422;
Atoms CB, CG, SD and CE of Met417;
Atoms CB, CG, CD1 and CD2 of Leu400 and Leu421;
Atoms CB, CG1, CG2, or CD1 of Ile424;
Backbone NH and carbonyl oxygen atoms of Ala578; and
Atoms CB, CG, ND1, CE1, NE2, and CD2 of His639.

Please add new claims 30 and 31 as follows:

30. (New) The method of claim 22, wherein said activity of cPLA₂ is lipid binding.

31. (New) The method of claim 22, wherein said activity of cPLA₂ is membrane binding.

D3
Cancel